为您找到"
n1048
"相关结果约100,000,000个
N1048 Nova II for Institutional High Abuse ... SPEC SHEET IES Specifications are subject to change without notice. Please consult your Kenall Customer Service for help with special requests at (800) 4 Kenall.
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
The Alliance trial, N1048, also referred to as PROSPECT (Preoperative Radiation Or Selective Preoperative radiation and Evaluation before Chemotherapy and TME), is a randomized phase II/III trial of the selective use of radiation therapy in intermediate risk clinical stage II-III rectal cancer.
N1048 NCCTG N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Kenall® NOVA II™ N1048-C-2-32-IS-DV Fluorescent Ceiling Fixture, (2) F32T8 Linear Fluorescent Lamp, 120 to 270 VAC
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT trial (Alliance N1048), which were reported during the Plenary Session of the 2023 ASCO Annual ...
View and Download kenall NOVA N1048 Series installation instructions online. NOVA N1048 Series outdoor light pdf manual download.
N1048 is a surface mount ceiling or wall luminaire with a 10"×48" ADA compliant lens and a 45W LED lamp. It has a constant current driver, a motion sensor option, and a limited five-year warranty.
The largest and most comprehensive search engine in the professional lighting industry.
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted.